Date of Award
Daniel B. Nichols, PhD
Suzanne Gantar, PhD
Constantine Bitsaktsis, PhD
Angela Klaus, PhD
Glioblastoma Multiforme, T98G, Apoptosis, PPAR, Immunoblotting, SRB
1,1-bis(3’idolyl)-1(aryl)methane compounds (BIM compounds) have been shown to have anti-cancer properties in colon cancer, bladder cancer, and leukemia cells. The purpose of this work was to determine if BIM compounds could be an effective treatment of glioblastoma multiforme. Sulforhodamine B (SRB) assays showed that 20µM of the BIM compounds could inhibit cellular proliferation of the T98G glioblastoma multiforme cell line over 72 hours. Then immunoblotting was used to analyze the molecular pathway induced by BIM compounds. An increase in the expression of both BAX and cleaved caspase 3 suggest BIM compounds activate programmed cell death, or apoptosis in glioblastoma cells. In conducting this work, I am hoping to contribute to the creation of a new treatment for glioblastoma multiforme that will minimize the negative side effects of traditional cancer treatments.
Brown, Margot C., "Bis-Indolyl Compounds and the Induction of Apoptosis in T98G Glioblastoma Multiforme Cells" (2022). Seton Hall University Dissertations and Theses (ETDs). 3046.